Trials / Completed
CompletedNCT02949830
A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)
A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients With Acute Intermittent Porphyria Who Have Completed a Previous Clinical Study With ALN-AS1
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the long-term safety, tolerability and pharmacokinetics of givosiran (ALN-AS1) in AIP patients who completed study ALN-AS1-001 (NCT02452372).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Givosiran | Givosiran by subcutaneous (SC) injection. |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2021-11-05
- Completion
- 2021-11-05
- First posted
- 2016-10-31
- Last updated
- 2024-03-12
- Results posted
- 2024-03-12
Locations
5 sites across 3 countries: United States, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02949830. Inclusion in this directory is not an endorsement.